Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics, Inc. (ZVRA)
:ZVRA
ZVRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.20 - $9.76
Previous CloseN/A
Volume189.47K
Average Volume (3M)534.86K
Market Cap
$377.73M
Enterprise Value$337.68M
Total Cash (Recent Filing)-$1.97M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 08, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding54,115,868
10 Day Avg. Volume561,586
30 Day Avg. Volume534,863
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)18.36
Price to Cash Flow (P/CF)-6.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit20.85
Enterprise Value/Ebitda-4.42
Forecast
1Y Price Target
$22.29Price Target Upside219.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Zevra Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Cash PositionThe sale of the Rare Pediatric Disease Priority Review Voucher for $150M provides a significant infusion of non-dilutive capital to strengthen the company's balance sheet.
Financial PerformanceSales of Miplyffa for Niemann-Pick Type C came in higher than expected, indicating strong market performance.
Regulatory ApprovalFDA approval of Miplyffa marks it as the first approved therapy for Niemann-Pick disease type C in the US, potentially allowing for rapid adoption among patients.
Bears Say
Reimbursement ChallengesA third of Miplyffa patients have been approved for reimbursement, and while many commercial payers have not yet made decisions about a formal policy, the vast majority of patients are able to get reimbursed.
---
Ownership Overview
0.63% Insiders
10.39% Mutual Funds
34.94% Other Institutional Investors
43.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZVRA FAQ
What was Zevra Therapeutics, Inc.’s price range in the past 12 months?
Zevra Therapeutics, Inc. lowest stock price was $4.20 and its highest was $9.76 in the past 12 months.
What is Zevra Therapeutics, Inc.’s market cap?
Zevra Therapeutics, Inc.’s market cap is $377.73M.
When is Zevra Therapeutics, Inc.’s upcoming earnings report date?
Zevra Therapeutics, Inc.’s upcoming earnings report date is May 08, 2025 which is in 22 days.
How were Zevra Therapeutics, Inc.’s earnings last quarter?
Zevra Therapeutics, Inc. released its earnings results on Mar 11, 2025. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.395 by -$0.275.
Is Zevra Therapeutics, Inc. overvalued?
According to Wall Street analysts Zevra Therapeutics, Inc.’s price is currently Undervalued.
Does Zevra Therapeutics, Inc. pay dividends?
Zevra Therapeutics, Inc. does not currently pay dividends.
What is Zevra Therapeutics, Inc.’s EPS estimate?
Zevra Therapeutics, Inc.’s EPS estimate is -0.18.
How many shares outstanding does Zevra Therapeutics, Inc. have?
Zevra Therapeutics, Inc. has 54,115,868 shares outstanding.
What happened to Zevra Therapeutics, Inc.’s price movement after its last earnings report?
Zevra Therapeutics, Inc. reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.395. Following the earnings report the stock price went down -1.859%.
Which hedge fund is a major shareholder of Zevra Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ZVRA
---
Zevra Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.29 (219.34% Upside)
$22.29 (219.34% Upside)
Blogger Sentiment
Bullish
ZVRA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 117.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $81.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.41%
12-Months-Change
Fundamentals
Return on Equity
-207.84%
Trailing 12-Months
Asset Growth
3.37%
Trailing 12-Months
Company Description
Zevra Therapeutics, Inc.
Zevra Therapeutics (ZVRA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases and central nervous system disorders. The company operates in the healthcare and biotechnology sectors, leveraging its expertise in drug development to bring novel treatments to market. Zevra Therapeutics' core products include a portfolio of proprietary drug candidates that are in various stages of clinical development, targeting unmet medical needs in niche patient populations.
---
ZVRA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements such as the successful launch and FDA approval of MIPLYFFA, along with record revenue and expansion plans. However, there were challenges with the slower than expected OLPRUVA launch and increased net loss. Overall, the positives outweigh the negatives due to the strong start of MIPLYFFA and financial stability.Read More>---
ZVRA Stock 12 Month Forecast
Average Price Target
$22.29
▲(219.34% Upside)
Technical Analysis
Best Analysts Covering ZVRA
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+18.05%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +18.05% per trade.
---